Glioblastoma post-operative imaging in neuro-oncology: current UK practice (GIN CUP study) by Booth, Thomas C. et al.
 
 
 
 
 
Edinburgh Research Explorer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Glioblastoma post-operative imaging in neuro-oncology: current
UK practice (GIN CUP study)
Citation for published version:
Booth, TC, Luis, A, Brazil, L, Thompson, G, Daniel, RA, Shuaib, H, Ashkan, K & Pandey, A 2020,
'Glioblastoma post-operative imaging in neuro-oncology: current UK practice (GIN CUP study)', European
Radiology. https://doi.org/10.1007/s00330-020-07387-3
Digital Object Identifier (DOI):
10.1007/s00330-020-07387-3
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Publisher's PDF, also known as Version of record
Published In:
European Radiology
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 03. Dec. 2020
NEURO
Glioblastoma post-operative imaging in neuro-oncology: current UK
practice (GIN CUP study)
Thomas C. Booth1,2 & Aysha Luis1,3 & Lucy Brazil4 & Gerry Thompson5 & Rachel A. Daniel1 & Haris Shuaib6,7 &
Keyoumars Ashkan8 & Anmol Pandey9
Received: 1 May 2020 /Revised: 13 August 2020 /Accepted: 7 October 2020
# The Author(s) 2020
Abstract
Objectives MRI remains the preferred imaging investigation for glioblastoma. Appropriate and timely neuroimaging in the
follow-up period is considered to be important in making management decisions. There is a paucity of evidence-based informa-
tion in current UK, European and international guidelines regarding the optimal timing and type of neuroimaging following
initial neurosurgical treatment. This study assessed the current imaging practices amongst UK neuro-oncology centres, thus
providing baseline data and informing future practice.
Methods The lead neuro-oncologist, neuroradiologist and neurosurgeon from every UK neuro-oncology centre were invited to
complete an online survey. Participants were asked about current and ideal imaging practices following initial treatment.
Results Ninety-two participants from all 31 neuro-oncology centres completed the survey (100% response rate). Most centres
routinely performed an early post-operative MRI (87%, 27/31), whereas only a third performed a pre-radiotherapy MRI (32%,
10/31). The number and timing of scans routinely performed during adjuvant TMZ treatment varied widely between centres. At
the end of the adjuvant period, most centres performed an MRI (71%, 22/31), followed by monitoring scans at 3 monthly
intervals (81%, 25/31). Additional short-interval imaging was carried out in cases of possible pseudoprogression in most centres
(71%, 22/31). Routine use of advanced imaging was infrequent; however, the addition of advanced sequences was the most
popular suggestion for ideal imaging practice, followed by changes in the timing of EPMRI.
Conclusion Variations in neuroimaging practices exist after initial glioblastoma treatment within the UK. Multicentre, longitu-
dinal, prospective trials are needed to define the optimal imaging schedule for assessment.
Key Points
• Variations in imaging practices exist in the frequency, timing and type of interval neuroimaging after initial treatment of
glioblastoma within the UK.
• Large, multicentre, longitudinal, prospective trials are needed to define the optimal imaging schedule for assessment.
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Abbreviations
ADC Apparent diffusion co-efficient
DCE Dynamic contrast enhanced
DSC Dynamic susceptibility contrast enhanced
DTI Diffusion tensor imaging
DWI Diffusion weighted imaging
EPMRI Early post-operative MRI
FLAIR Fluid-attenuated inversion recovery
MGMT O6-Methylguanine-DNA methyltransferase
MRS Magnetic resonance spectroscopy
PCV Procarbazine, lomustine and vincristine
PET Positron emission tomography
PRMRI Pre-radiotherapy MRI
RANO Response Assessment in Neuro-Oncology
SWI Susceptibility weighted imaging
TMZ Temozolomide
WHO World Health Organization
Introduction
Glioblastoma is the most common and aggressive primary
malignant brain tumour in adults. It carries an annual inci-
dence of 4.64 per 100,000 in England, with a peak between
65 and 75 years of age [1]. The current standard of care for
newly diagnosed patients is maximal safe resection, followed
by radiotherapywith concomitant and adjuvant temozolomide
(TMZ) [2]. Despite this regimen, glioblastoma almost always
recurs; the median overall survival is 14.6 months, whilst 5-
year survival is below 10% [3].
Clinical review and serial neuroimaging remain the primary
monitoring tools used to evaluate disease status and assess treat-
ment response. However, on review of current UK, European
and international guidelines, there is considerable variation and a
paucity of evidence-based information regarding the optimal fre-
quency, timing and type of neuroimaging following initial neu-
rosurgical intervention [4–10]. Nevertheless, pragmatic neuroim-
aging time points are typically used in routine clinical practice
which include an early post-operative MRI (EPMRI), a pre-
radiotherapy MRI (PRMRI) and time points assessing the re-
sponse of chemoradiotherapy both during and following comple-
tion of adjuvant TMZ [4–10].
EPMRI is frequently performed primarily to determine the
extent of resection and to assess residual disease [11, 12].
There are recommendations that the EPMRI should be per-
formed within 48–72 h due to the confounding effects of surgi-
cally induced contrast enhancement [11, 13]. The primary pur-
pose for PRMRI is to delineate target volumes for radiotherapy
planning, although this can also be achieved using fusion of the
EPMRI with computed tomography (CT) in many cases [14].
Following completion of radiotherapy and concomitant
TMZ, the first MRI examination is recommended to be per-
formed 4–12 weeks subsequently [4, 7]. At this time point,
approximately 20–30% of patients demonstrate a treatment-
related effect , termed ‘pseudoprogression’ [15] .
Pseudoprogressionmanifests as a transient increase in contrast
enhancement and remains stable or eventually subsides with-
out any change in treatment. Pseudoprogression appears to be
the imaging manifestation of a subacute treatment-related tis-
sue reaction which comprises inflammation, oedema, and in-
creased permeability of the blood-brain barrier. The precise
pathophysiological mechanism is still poorly understood, but
histologic features typically associated with treatment effects
such as bland necrosis with prominent vascular fibrinoid ne-
crosis, reactive gliosis, oedema, demyelination and vascular
hyalinisation are seen in those with pseudoprogression [16].
Pseudoprogression appears within 6 months of radiotherapy
completion [17, 18], which is earlier than radiation necrosis
[15, 19], another post-treatment-related effect (PTRE).
Pseudoprogression appears to be more frequent in patients
with a methylated MGMT gene promoter [15, 20].
Differentiating pseudoprogression from true progression has
important implications in glioblastoma management but remains
a major challenge as no standardised imaging biomarker has
been definitively proven to be reliable [13]. In cases of suspected
pseudoprogression, short-interval confirmatory MRI is recom-
mended within 4–6 weeks whilst adjuvant TMZ treatment is
continued [4, 9]. However, conventional structural imaging alone
is often insufficient and unreliable. Advanced MR imaging tech-
niques, such as perfusion imaging (dynamic susceptibility con-
trast-enhanced, DSC), permeability imaging (dynamic contrast-
enhanced, DCE), 1H-magnetic resonance spectroscopy (MRS)
and position emission tomography (PET) using radiolabelled
amino acid tracers (L-[methyl-11C]methionine [MET], 18F-
fluoroethyl-tyrosine [FET], 18F-fluoro-L-dihydroxy-phenylala-
nine [FDOPA] and 11C-alpha-methyl-L-tryptophan [AMT]),
can provide additional physiological and metabolic information
which may be helpful in distinguishing tumour progression from
pseudoprogression [21–41].
In cases where tumour progression is confirmed with neuro-
imaging, management typically consists of second-line chemo-
therapy including the combination of procarbazine, lomustine
and vincristine (PCV) [9, 42, 43], TMZ re-challenge [44, 45] or
supportive care. There is less evidence to support re-irradiation
and second surgery [9, 46, 47]. The specific strategy used de-
pends on factors including performance status, risk of disability
and prior treatment. In the absence of any tumour progression, a
further MRI examination is generally recommended at the end
of adjuvant TMZ [4], which serves as a new baseline for sub-
sequent MRI examinations at 3–4 monthly intervals [9].
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As the majority of the above recommendations were moti-
vated by a need for reference standards in neuro-oncology
clinical trials [48], we suspected that real-world neuro-oncol-
ogy follow-up imaging practices vary considerably between
UK centres. Given the lack of reliable and detailed data on
current practice, we have surveyed all UK neuro-oncology
centres to determine how neuroimaging is currently being
used in the management of glioblastoma. Importantly, the
survey will provide baseline data which is required to inform
the design of studies aimed to optimise follow-up MRI imag-
ing practice.
Methods
Participants
The UK Research Ethics Service (RES) provided written con-
firmation that ethical approval was not necessary for this
study. Eligible participants were neuro-oncologists, neurora-
diologists and neurosurgeons from all thirty-one neuro-oncol-
ogy centres within the UK (public National Health Service
academic centres). The participants were specialty leads or
joint leads for their respective neuro-oncological service. As
no national database of these neuro-oncology experts exists,
we therefore identified potential participants’ contact details
through institution websites and by liaison with relevant
learned societies and known experts.
Survey design
The survey featured forty-three questions, divided into single
choice, multiple choice and free text questions (Appendix 1).
Participants were asked specialty-specific and cross-specialty
questions regarding the current imaging practices following
initial treatment for glioblastoma at their institution, as well
as their opinion on ideal practice, which was defined as prac-
tice without time or cost constraint.
We used tailored design and bimodal methodology [49] to
increase response rates and obtain high-quality feedback. The
questionnaire was designed with feedback from a neuro-
oncology charity (a member of UK’s James Lind Alliance
Priority Setting Partnership who wish to establish the value
and benefit of neuro-oncological interval imaging) [50] and
improved thereafter following pilot testing by neuro-oncolo-
gists, neuroradiologists and neurosurgeons from two centres
who were specialty leads for their respective neuro-
oncological service. There were no concerns regarding recall
bias; nonetheless, two elements of the design reduced this risk.
First, every individual neuro-oncologist, neuroradiologist and
neurosurgeon who was the specialty lead at their respective
neuro-oncological service was asked to answer the question-
naire to give a collective centre response for the core
questions. Second, only the specialty leads were selected to
complete the questionnaire because typically they are in-
volved in designing imaging protocols and are aware of annu-
al audit findings.
An online survey tool, Survey Monkey (www.
surveymonkey.com), was used for data collection. Each
participant was invited to complete the online survey via e-
mail. Multiple individualised follow-up emails were sent to
ensure completion of the survey. Where we received data
from both joint leads, the questionnaire which contained more
detailed responses was used for final analysis.
Statistical analysis
We compiled data from the completed surveys in Microsoft
Excel (Microsoft Corp). SPSS (IBM Corp) was used for de-
scriptive statistical analysis and to make comparisons between
groups using the chi-squared test (Yates corrected). For small-
er sample sizes, Fisher exact test was used. Statistical signif-
icance was set at p < 0.05.
Results
Subject characteristics
We identified 124 eligible participants from 31 centres; of
these, 109 completed the survey. One duplicate response
was removed. In twelve centres where joint leads from the
same specialty responded, the questionnaire which contained
the more detailed response was used for final analysis. There
were no discrepancies in any of the joint responses. The final
analysis comprised 92 respondents across 31 centres, includ-
ing one neuro-oncologist who covered two centres. Thus,
100% centre and specialty lead response rates were achieved.
The characteristics of survey respondents are summarised in
Table 1.
EPMRI
Most centres (87%, 27/31) reported that they routinely per-
form EPMRI (Fig. 1). The main reasons given for performing
EPMRI were to quantify residual tumour volume and estab-
lish a baseline for subsequent examinations (Table 2). There
were no significant differences in the rationale for EPMRI
between specialties (p = 0.59).
In response to specialty-specific questions, EPMRI was
reported to be used frequently by neuroradiologists and
neuro-oncologists for purposes of treatment assessment and
chemoradiotherapy planning respectively (71%, 22/31; 70%,
21/30). However, only a third of neurosurgeons (35%, 11/31)
stated that the EPMRI formed an integral part of their
decision-making process for further debulking surgery. It
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was reported that further debulking surgery was ultimately
undertaken in only a small percentage (5–10%) of patients.
PRMRI
Ten centres (32%, 10/31) reported that MRI was performed
routinely prior to the commencement of radiotherapy (Fig. 1).
A further eight centres (26%, 8/31) reported that co-registered
CT was performed instead. In the remaining fourteen centres
(45%, 14/31), it was unclear whether imaging was consistent-
ly performed at this time point. The most frequently reported
reason for performing the PRMRI was radiotherapy planning
(83%, 25/30). There were no significant differences in the
rationale for PRMRI between specialties (Table 2; p = 0.74).
MRI performed during adjuvant TMZ treatment
Twenty-three centres (74%, 23/31) reported that they had a
standardised protocol for the adjuvant TMZ period (Fig. 1);
three centres (10%, 3/31) avoided MRI during this period
altogether; the remaining five centres did not provide a clear
standardised protocol (16%, 5/31). The number and timing of
scans routinely performed during adjuvant TMZ treatment
varied widely (Table 3). Similarly, the standardised protocols
implemented when there was suspected progression or new
clinical symptoms also varied (Table 3). Most centres per-
formed anMRI at the end of the adjuvant period (71%, 22/31).
MRI performed after adjuvant TMZ treatment
All centres reported to have a standardised protocol for disease
monitoring following the completion of adjuvant TMZ treat-
ment (100%, 31/31; Fig. 1). Most centres performed MRI
scans at 3 monthly intervals (81%, 25/31), although the length
of follow-up was more variable (Table 4). In comparison to
the adjuvant TMZ period, a significantly smaller proportion of
centres reported having a standardised protocol to implement
following suspected progression (11/31 vs 22/31, p = 0.019),
opting instead for a more case-based approach (45%, 14/31).
Assessing treatment response
Only 23% (7/31) of centres assessed treatment response based
on the RANO criteria [13], whilst the MacDonald criteria [51]
were not used at all (Table 5).
Imaging sequences and technique
Structural sequences (pre- and post-contrast T1-weighted, T2-
weighted, FLAIR) were used in all cases where the
standardised protocol was described (Fig. 2). Diffusion
weighted imaging (DWI) was used in the majority of
EPMRI (85%, 23/27), during adjuvant TMZ (83%, 19/23)
and after adjuvant TMZ (84%, 26/31; Fig. 2). Routine use of
advanced imaging (DSC, DCE and/or MRS) on all patients
was infrequent and limited to adjuvant TMZ and post-
adjuvant TMZ periods (Fig. 2). Neuroradiologists from eleven
centres (35%, 11/31), however, reported that advanced imag-
ing was performed in selective cases to help differentiate be-
tween pseudoprogression and true progression during the ad-
juvant period ((p < 0.001). A further inconsistency between
the specialties was seen during the EPMRI time point, where-
by neuroradiologists reported more frequent use of volumetric
imaging (p = 0.004).
Ideal practice
In response to questions regarding ideal practice, thirty-seven
respondents (40%, 37/92) reported that they would change
their imaging protocol. Thirty-five respondents (38%, 35/92)
did not suggest any changes, and the remaining twenty re-
spondents (22%, 20/92) did not give a response.
Table 1 Background characteristics of 92 respondents from 31 neuro-
oncology centres included for final analysis. All respondents were leads
or joint leads for their respective neuro-oncological service. All respon-
dents were UK consultant grade (i.e. independent practitioner)
Characteristic Value, n (%)
Speciality of respondents
Neuroradiologist 31 (34%)
Neurosurgeon 31 (34%)
Neuro-oncologist 30* (33%)
Location of respondents
East Midlands 3 (3%)
East of England 3 (3%)
South-East 9 (10%)
London 18 (20%)
North-East England 6 (7%)
North-West England 11 (12%)
Northern Ireland 3 (3%)
Scotland 12 (13%)
South-West 6 (7%)
Wales 3 (3%)
West Midlands 9 (10%)
Yorkshire 9 (10%)
Number of newly diagnosed glioblastoma cases per centre per year
0 < 50 3 (10%)
50 < 100 7 (22%)
100 < 150 13 (42%)
150 < 200 8 (26%)
> 200 0 (0%)
Time as consultant
Years (median; range) 11; 1–29
*A single neuro-oncologist covered two centres
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Amongst those who suggested change in their current im-
aging protocol, approximately half (46%, 17/37) reported that
adding advanced sequences such as DSC, DCE, MRS or PET
would provide meaningful benefit, for subsequent comparison
and to help differentiate between tumour progression and
treatment-related changes. Although responses did not differ
significantly between the three specialties questioned at
EPMRI, PRMRI, and during and after adjuvant TMZ with
regard to changing sequences (p = 0.1, p = 0.1, p = 0.6 and
p = 0.8 respectively), we made three observations.
Neuroradiologists were the main advocates for proposing ad-
vancedMRI during and following the adjuvant period (100%,
14/14). On the other hand, neuro-oncologists were more likely
to suggest that further evidence is needed for analytical and
clinical validation of these modalities in routine clinical prac-
tice (56%, 5/9). Conversely, neurosurgeons preferred to rou-
tinely add a volumetric acquisition to the EPMRI protocol to
assess residual tumour volume (43%, 6/14; p = 0.04).
In terms of timing, it was noted that a small number of
respondents (14%, 5/37), predominantly neurosurgeons, stat-
ed that they would want the EPMRI to be performed earlier
than 72 h, whereas a minority of neuroradiologists stated that
they would delay the timing to beyond 72 h to coincide with
radiotherapy planning (8%, 3/37; p < 0.001). A further ideal
practice suggestion was to ensure that EPMRI scans were
available to all patients undergoing debulking surgery, includ-
ing out of hours (27%, 10/37). Only a few respondents,
predominantly neuro-oncologists, reported that they would
add PRMRI (11%, 4/37; p = 0.7).
Discussion
Summary of findings
The GIN CUP study highlighted the variation in imaging
practices in the treatment and follow-up periods of glioblasto-
ma amongst the 31 neuro-oncological units in the UK. Over
80% of centres routinely performed EPMRI whereas only
32% performed PRMRI. During adjuvant TMZ treatment,
there was considerable variation in the timing and frequency
of imaging. There was more consistency at the end of the
adjuvant period, at which point most centres (71%) performed
MRI routinely, followed by monitoring scans at 3 monthly
intervals (81%). The addition of advanced sequences was
the most popular suggestion for ideal imaging practice,
followed by changes in the timing of EPMRI.
Comparison with other studies and study relevance
Over two decades ago, a prospective study showed that the
volume of residual enhancing disease seen on EPMRI was an
independent prognostic biomarker for both progression and
overall survival [11]. This formed a rationale to perform
Table 2 The rationale given for performing the early post-operative MRI (EPMRI) and pre-radiotherapy MRI (PRMRI)
Early post-operative MRI Neuroradiologist Neurosurgeon Neuro-
oncologist
Total
Purpose
Establish amount of residual tumour 27 29 27 83 (90%)
Baseline to allow later assessment of treatment response 25 24 22 71 (77%)
Plan radiotherapy 12 14 21 47 (51%)
Differentiate between residual tumour and haemorrhage 16 13 14 43 (47%)
Differentiate between residual tumour and post-operative
enhancement
15 11 14 40 (43%)
Differentiate between residual tumour and post-operative ischaemia 14 13 10 37 (40%)
Establish amount of residual tumour suitable for further resection 12 14 10 36 (39%)
p = 0.59
Speciality specific
EPMRI used to assess treatment response on later MRI 22 (71%) – –
EPMRI used to decide on further debulking surgery – 11 (35%) –
EPMRI used in the management of chemoradiotherapy – – 21 (70%)
Pre-radiotherapy MRI
Purpose
Plan radiotherapy 9 6 10 25 (83%)
Baseline to allow later assessment of treatment response 7 2 3 12 (40%)
Establish amount of residual tumour 4 2 2 8 (27%)
Establish amount of residual tumour suitable for further resection 1 0 1 2 (7%)
p = 0.74
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EPMRI, which RANO subsequently advocated for use in trials
in 2010 [13]. Compared to a 2010 survey of UK neuro-oncol-
ogists, our findings suggest an increase in the popularity of
EPMRI in routine clinical practice (80% vs 50%) [4].
Our survey revealed that the most common reason for under-
taking EPMRI was to determine the extent of residual tumour.
However, recent studies have shown false-positive results where
non-neoplastic enhancement appears within 72 h of surgery [52,
53]. Furthermore, 24% of cases appear to give false-negative
results, as proven by histopathology or short-term follow-up
[54]. In the recent era of TMZ chemotherapy and advanced
neurosurgical techniques, a retrospective study demonstrated that
EPMRI after tumour resection did not significantly affect overall
survival [55]. In our study, the identification of residual disease
infrequently altered subsequent management, as evidenced by
neurosurgeons self-reporting that only 5–10% of patients under-
go early repeat resection based on findings from EPMRI. This
early repeat resection rate was 0% in a recent UK survey of 22
neurosurgical units, despite 16% (13/80) of cases being deemed
operable [56]. It is possible that such evidencemight explainwhy
some centres choose not to perform EPMRI.
There is evidence that PRMRI could provide a more accu-
rate baseline for subsequent imaging studies compared to
EPMRI, due to the detection of any interval changes occurring
between EPMRI and the initiation of chemoradiotherapy [57].
These changes include tumour growth [57–59] and new reac-
tive non-neoplastic enhancement [11, 52, 53], both of which
can confound treatment response assessment on subsequent
imaging studies.
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Fig. 1 Percentage of centres that perform MRI at the different time
points. All centres performed MRI after adjuvant TMZ, most centres
performed MRI early post-operatively and during adjuvant TMZ treat-
ment, whereas only 32% of centres routinely performed pre-radiotherapy
MRI. TMZ= temozolomide
Table 3 Distribution of the
number and timing of scans
routinely performed during
adjuvant temozolomide (TMZ).
Also shown are the standardised
protocols implemented when
there is suspected progression or
new clinical symptoms
Number of scans during adjuvant period (not including post-cycle 6 TMZ) Number of centres, n (%)
0 3 (10%)
1 7 (23%)
2 12 (39%)
3 4 (13%)
No standardised protocol 5 (16%)
Timing of first post-chemoradiotherapy scan Number of centres, n (%)
4 weeks 12 (39%)
8 weeks 1 (3%)
12 weeks 10 (32%)
End of TMZ cycle 6 only 3 (10%)
No standardised protocol 5 (16%)
Protocol in suspected progression Number of centres, n (%)
Additional imaging at 4–6 weeks 14 (45%)
Additional imaging over 4–12 weeks 8 (26%)
No standardised protocol 6 (19%)
No routine scans performed during adjuvant period 3 (10%)
Protocol if symptomatic during this period Number of centres, n (%)
Initial CT, followed by MRI 11 (35%)
MRI 20 (65%)
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Pseudoprogression and radiation necrosis are two well-
documented forms of PTRE. Pseudoprogression generally
occurs within the six months following completion of che-
moradiotherapy, and resolves or stabilises without addi-
tional treatment [15, 17–19, 60], whereas radiation necro-
sis generally occurs beyond 6 months, up to several years
after radiotherapy, and is often more severe and progres-
sive [15, 19]. Structural imaging alone cannot reliably dis-
criminate between true progression and PTRE, due to the
common features of contrast enhancement, perilesional
oedema-like appearance and mass effect. Over the last
two decades, there have been numerous promising studies
to make this distinction, including the use of DSC, MRS
and amino acid PET (Supplementary Table 1) [21–41, 61].
In our study, advanced techniques were used by only 10%
of centres routinely and a third of centres in selected cases.
This is in contrast to a survey of neuroradiologists across
220 European institutions in 2016, which reported routine
use of advanced imaging for glioma follow-up (82% DSC,
80% MRS) [62]. However, the response rate for this
European survey was 3%, and the results may not be rep-
resentative of UK (or European) practice. The relatively
low routine use of advanced imaging in our study might
be related to the limited availability of expertise and soft-
ware, as well as the increased operational costs, although
many respondents suggested that advanced imaging tech-
niques would improve their practice.
In our study, the largest variation in timing of MRI scans
existed during the adjuvant period, which is comparable to a
previous study [4]. In cases of suspected progression, only
half of the centres emulated the 4–6 week “confirmatory” scan
recommendation from RANO research guidelines [13]. One
potential explanation for this is that two consecutive MRI
within a short interval (4–6 weeks) may offer limited diagnos-
tic value, particularly if they are performed during the enlarge-
ment phase of pseudoprogression [17]. Other limitations with
imaging research guidelines have been described which might
also have reduced their influence in a clinical setting [63].
Most centres used the same sequences at each of the dif-
ferent time points. The sequences included pre- and post-
contrast T1-weighted, T2-weighted, FLAIR and DWI, apart
from the PRMRI when DWI sequences were obtained infre-
quently. Consensus recommendations by a group of predom-
inantly US experts for a standardised imaging protocol in trials
[48] include pre- and post-contrast volumetric T1-weighted
imaging, T2-weighted, FLAIR and DWI sequences. In our
study, the use of volumetric imaging appeared to be underem-
ployed; this was highlighted by neurosurgeons, who valued
volumetric images as part of their ideal practice.
Strengths and limitations
This was the first study to unequivocally capture UK neuro-
oncology imaging practices by achieving a 100% response
rate across three specialties from lead or joint lead consultants
at all UK neuro-oncology centres. The 100% yield is impor-
tant as it eliminated “nonresponse bias” due to an unrepresen-
tative cohort response. The selection of these experts also
eradicates “sampling bias” as these are the most expert clini-
cians for the subject matter. Our questionnaire was compre-
hensive and likely to capture the details of imaging practices
following treatment for high-grade gliomas. There is benefit
of including open-ended questions because they are not lim-
ited to a predetermined set of possible answer choices in order
to extract more granular information. Indeed, after coding the
Table 5 Assessment of treatment
response during and after
adjuvant temozolomide (TMZ)
Assessment of treatment response No. of centres,
n (%)
MacDonald criteria based 0 (0%)
RANO criteria based 7 (23%)
Standardised protocol not based on either MacDonald or RANO criteria 12 (39%)
No standardised protocol 12 (39%)
Table 4 Distribution of the imaging intervals and duration of imaging
after completion of adjuvant temozolomide (TMZ). Also shown is the
standardised protocol implemented where there is suspected progression
Scan interval and duration No. of centres, n (%)
3 monthly intervals for 6 months 3 (10%)
3 monthly intervals for 12 months 4 (13%)
3 monthly intervals for 18 months 1 (3%)
3 monthly intervals for 24 months 9 (29%)
3 monthly intervals for life 8 (26%)
4 monthly intervals for 18 months 2 (6%)
6 monthly intervals for life 4 (13%)
Protocol in suspected progression No. of centres, n (%)
Additional imaging at 4–6 weeks 7 (23%)
Additional imaging at 6–12 weeks 4 (13%)
No standardised protocol 14 (45%)
No additional confirmatory scan 6 (19%)
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granular information, a qualitative data analysis (QDA) pro-
vides useful information. However, although the question-
naire was designed with care and was improved after pilot
testing, responses may reflect varying interpretation of the
questions. It is also conceivable there may have been “recall
bias”—after all, recall bias is almost impossible to entirely
eradicate in surveys. However, the inclusion of experts who
are typically involved in all aspects of neuro-oncology admin-
istration including attending weekly multi-disciplinary team
meetings and planning departmental guidelines minimises re-
call bias. Additionally, questions regarding ideal practice only
received responses from 50 to 60% of respondents distributed
evenly across the three specialties. The reasons for poor re-
sponse in this part of the survey are uncertain. Furthermore,
although a health economic resource use analysis is beyond
the remit of the study, it would have been interesting to ex-
plore resource use for each neuro-oncology centre, as it is
possible this may have influenced imaging practices
(Appendix 2). Our survey did not also address the emergence
of novel therapies, such as immunotherapy and tumour-
treating fields; however, these are not currently recommended
as second-line treatment options in the UK outside of research
trials.
Unanswered questions and future directions
The variations in imaging practices elucidated by this
study are most likely due to a lack of consensus and
high-level evidence on the optimal schedule for imaging
investigations during and after glioblastoma treatment. In
particular, there has been no definitive study which ad-
dresses the question of how often MRI should be obtained
in the post-treatment follow-up period. It is noteworthy
that establishing the value and benefit of neuro-
oncological interval imaging forms the second of ten pri-
orities proposed by the UK’s James Lind Alliance Priority
Setting Partnership, an organisation which aims to raise
awareness for important research questions [50]. Our
study records current clinical practice and highlights that
there is variation between centres. We reiterate that the
study does not aim to present optimal practice. To achieve
optimal practice in this heterogeneous patient pathway
where there are multiple co-variates, large, multicentre,
longitudinal, prospective trials, possibly informed by
data-driven machine learning algorithms [64], are now
needed. Such studies could define the optimal time points
for assessment and determine whether neuroimaging per-
formed at each defined time point after initial glioblasto-
ma treatment results in a real change in management and,
more importantly, results in a change in patient outcomes
such as morbidity and overall survival.
It is also noteworthy that if imaging could be performed
without time or cost constraint, the expert community would
add advanced sequences to current protocols. Mismatch be-
tween UK experts’ existing and perceived ideal MRI follow-
up imaging regimens may reflect resource constraints and
concerns over non-harmonised and non-validated advanced
imaging protocols. This finding might motivate further
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development of cost-effective, harmonised and validated ad-
vanced sequences.
Conclusion
The GIN CUP study assessed the current imaging practices
amongst UK neuro-oncology centres and provided baseline
data to inform future practice. We have shown definitively
that variations in neuroimaging practices exist after initial
glioblastoma treatment within the UK. Centre variation is un-
likely to be in the best interests of all UK patients and is likely
to reflect a lack of consensus and high-level evidence on the
optimal schedule for imaging investigations during and after
glioblastoma treatment. A validated post-operative imaging
protocol with definitive evidence that outcomes are improved
is now required. Multicentre, longitudinal, prospective trials
interrogating protocols are recommended as is the develop-
ment of efficient, harmonised and validated advanced
sequences.
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